Published in Transl Oncol on February 01, 2010
Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010) 1.15
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol (2013) 0.99
In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model. Mol Imaging Biol (2011) 0.92
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
Clinical applications in molecular imaging. Pediatr Radiol (2010) 0.80
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants. J Nucl Med (2016) 0.76
Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Transl Androl Urol (2012) 0.75
SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. Toxins (Basel) (2010) 0.75
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol (2006) 3.19
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther (2007) 2.91
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
New approaches for imaging tumour responses to treatment. Nat Rev Cancer (2008) 2.38
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol (2008) 2.29
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med (2007) 1.99
Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic (2006) 1.78
Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (2008) 1.73
Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene (1999) 1.71
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res (2006) 1.70
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res (2007) 1.52
A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia (2009) 1.52
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia (2009) 1.52
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol (2008) 1.51
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs (2008) 1.46
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res (2007) 1.32
Is PET always an advantage versus planar and SPECT imaging? Eur J Nucl Med Mol Imaging (2008) 1.15
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol (2007) 1.14
Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell (2004) 1.10
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer (2009) 1.08
Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res (2008) 1.07
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther (2007) 1.06
Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med (2007) 1.03
Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol (2008) 0.90
Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol (2008) 0.89
Cutting off cancer's supply lines. Nature (2009) 0.87
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer (2008) 0.85
Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjug Chem (2008) 0.83
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med (2007) 1.99
Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med (2006) 1.68
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol (2009) 1.30
Silica encapsulation of fluorescent nanodiamonds for colloidal stability and facile surface functionalization. J Am Chem Soc (2013) 1.17
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther (2005) 1.16
Direct measurement of DNA bending by type IIA topoisomerases: implications for non-equilibrium topology simplification. Nucleic Acids Res (2011) 1.10
Multiplexing with multispectral imaging: from mice to microscopy. ILAR J (2008) 1.08
Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia (2009) 1.06
Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials (2006) 1.04
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging (2006) 1.02
VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol (2008) 0.98
Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjug Chem (2006) 0.97
Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem (2006) 0.97
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med (2013) 0.95
ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol (2010) 0.95
Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother (2006) 0.94
Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med (2004) 0.93
In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model. Mol Imaging Biol (2011) 0.92
Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol (2008) 0.90
Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem (2006) 0.90
Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med (2010) 0.90
Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology (Berl) (2010) 0.89
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia (2010) 0.88
Targeting the unfolded protein response in cancer therapy. Methods Enzymol (2011) 0.87
Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. Am J Physiol Endocrinol Metab (2007) 0.87
Molecular vehicles for targeted drug delivery. Bioconjug Chem (2002) 0.86
Single-molecule study of metalloregulator CueR-DNA interactions using engineered Holliday junctions. Biophys J (2009) 0.86
Fluorescence imaging of vascular endothelial growth factor in tumors for mice embedded in a turbid medium. J Biomed Opt (2010) 0.86
Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med (2009) 0.86
Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature. Adv Genet (2009) 0.86
SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem (2009) 0.85
Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism (2003) 0.84
Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes (2002) 0.84
Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjug Chem (2008) 0.83
PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging (2011) 0.83
Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.83
Adapter protein for site-specific conjugation of payloads for targeted drug delivery. Bioconjug Chem (2004) 0.82
Quantitative characterization of fluorophores in multi-component nanoprobes by single-molecule fluorescence. Biomed Opt Express (2011) 0.82
Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif (2002) 0.81
In vivo comparison of atherosclerotic plaque progression with vessel wall strain and blood flow velocity in apoE(-/-) mice with MR microscopy at 17.6 T. MAGMA (2009) 0.81
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. J Nucl Med (2011) 0.81
A noninvasive [99mTc]DTPA SPECT/CT imaging methodology as a measure of lung permeability in a guinea pig model of COPD. Mol Imaging Biol (2011) 0.78
Characterization of a recombinant form of annexin VI for detection of apoptosis. Bioconjug Chem (2010) 0.77
Assembly of targeting complexes driven by a single-chain antibody. J Immunol Methods (2004) 0.77
Humanized docking system for assembly of targeting drug delivery complexes. J Control Release (2003) 0.77
Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery. Protein Eng (2003) 0.76
Imaging VEGF receptor expression to identify accelerated atherosclerosis. EJNMMI Res (2014) 0.75
SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. Toxins (Basel) (2010) 0.75
[99mTc]Annexin V-128 SPECT Monitoring of Splenic and Disseminated Listeriosis in Mice: a Model of Imaging Sepsis. Mol Imaging Biol (2015) 0.75
A "dock and lock" approach to preparation of targeted liposomes. Methods Mol Biol (2010) 0.75